O	0	8	Extended
O	9	17	efficacy
O	18	21	and
O	22	28	safety
O	29	31	of
B-intervention	32	41	denosumab
O	42	44	in
B-eligibility	45	51	breast
I-eligibility	52	58	cancer
I-eligibility	59	67	patients
I-eligibility	68	72	with
I-eligibility	73	77	bone
I-eligibility	78	88	metastases
I-eligibility	89	92	not
I-eligibility	93	102	receiving
I-eligibility	103	108	prior
I-eligibility	109	123	bisphosphonate
I-eligibility	124	131	therapy
O	131	132	.

O	133	142	Denosumab
O	142	143	,
O	144	145	a
O	146	151	fully
O	152	157	human
O	158	168	monoclonal
O	169	177	antibody
O	178	180	to
O	181	186	RANKL
O	186	187	,
O	188	198	suppresses
O	199	203	bone
O	204	214	resorption
O	214	215	.

O	216	220	This
O	221	226	study
O	227	236	evaluated
O	237	240	the
O	241	248	effects
O	249	251	of
O	252	261	denosumab
O	262	264	in
O	265	266	i
O	266	267	.
O	268	269	v
O	269	270	.
O	271	285	bisphosphonate
O	286	287	(
O	287	289	IV
O	290	292	BP
O	292	293	)
O	293	294	-
O	294	296	na
O	296	297	ï
O	297	299	ve
O	300	308	patients
O	309	313	with
O	314	320	breast
O	321	327	cancer
O	327	328	-
O	328	335	related
O	336	340	bone
O	341	351	metastases
O	351	352	.

O	353	361	Eligible
O	362	367	women
O	368	369	(
O	369	370	n
O	371	372	=
B-total-participants	373	376	255
O	376	377	)
O	377	378	,
O	379	389	stratified
O	390	392	by
O	393	397	type
O	398	400	of
O	401	415	antineoplastic
O	416	423	therapy
O	423	424	,
O	425	429	were
O	430	440	randomized
O	441	443	to
O	444	445	1
O	446	448	of
O	449	450	5
O	451	458	blinded
O	459	468	denosumab
O	469	476	cohorts
O	477	479	or
O	480	482	an
B-control	483	487	open
I-control	487	488	-
I-control	488	493	label
I-control	494	496	IV
I-control	497	499	BP
O	500	506	cohort
O	506	507	.

O	508	517	Denosumab
O	518	521	was
O	522	534	administered
O	535	536	s
O	536	537	.
O	537	538	c
O	538	539	.
O	540	545	every
O	546	547	4
O	548	553	weeks
O	554	555	(
O	555	557	30
O	557	558	,
O	559	562	120
O	562	563	,
O	564	566	or
O	567	570	180
O	571	573	mg
O	573	574	)
O	575	577	or
O	578	583	every
O	584	586	12
O	587	592	weeks
O	593	594	(
O	594	596	60
O	597	599	or
O	600	603	180
O	604	606	mg
O	606	607	)
O	608	615	through
O	616	618	21
O	619	624	weeks
O	624	625	.

O	626	631	Final
O	632	640	efficacy
O	641	648	results
O	649	652	for
O	653	655	up
O	656	658	to
O	659	661	25
O	662	667	weeks
O	668	671	are
O	672	680	reported
O	680	681	,
O	682	691	including
O	692	702	percentage
O	703	709	change
O	710	714	from
O	715	723	baseline
O	724	726	in
O	727	732	urine
O	733	734	N
O	734	735	-
O	735	746	telopeptide
O	747	756	corrected
O	757	760	for
O	761	771	creatinine
O	772	773	(
O	773	777	uNTx
O	777	778	/
O	778	780	Cr
O	780	781	)
O	782	785	and
O	786	795	incidence
O	796	798	of
O	799	807	skeletal
O	807	808	-
O	808	815	related
O	816	822	events
O	823	824	(
O	824	827	SRE
O	827	828	)
O	828	829	.

O	830	836	Safety
O	837	844	results
O	845	848	are
O	849	857	reported
O	858	865	through
O	866	869	the
O	870	873	end
O	874	876	of
O	877	883	follow
O	883	884	-
O	884	886	up
O	887	888	(
O	888	890	up
O	891	893	to
O	894	896	57
O	897	902	weeks
O	902	903	)
O	903	904	.

O	905	907	At
B-outcome	908	912	week
I-outcome	913	915	13
I-outcome	916	919	and
I-outcome	920	922	25
I-outcome	922	923	,
I-outcome	924	927	the
I-outcome	928	934	median
I-outcome	935	942	percent
I-outcome	943	950	changes
I-outcome	951	953	in
I-outcome	954	958	uNTx
I-outcome	958	959	/
I-outcome	959	969	creatinine
I-outcome	970	971	(
I-outcome	971	973	Cr
I-outcome	973	974	)
O	975	980	among
O	981	989	patients
O	990	994	with
O	995	1005	measurable
O	1006	1010	uNTx
O	1011	1015	were
B-iv-cont-median	1016	1017	-
I-iv-cont-median	1017	1019	73
I-iv-cont-median	1019	1020	%
O	1021	1024	and
B-iv-cont-median	1025	1026	-
I-iv-cont-median	1026	1028	75
I-iv-cont-median	1028	1029	%
O	1030	1033	for
O	1034	1037	the
O	1038	1044	pooled
O	1045	1054	denosumab
O	1055	1061	groups
O	1062	1065	and
B-cv-cont-median	1066	1067	-
I-cv-cont-median	1067	1069	79
I-cv-cont-median	1069	1070	%
O	1071	1074	and
B-cv-cont-median	1075	1076	-
I-cv-cont-median	1076	1078	71
I-cv-cont-median	1078	1079	%
O	1080	1083	for
O	1084	1087	the
O	1088	1090	IV
O	1091	1093	BP
O	1094	1099	group
O	1099	1100	.

O	1101	1106	Among
O	1107	1115	patients
O	1116	1120	with
O	1121	1122	>
O	1123	1125	or
O	1126	1127	=
O	1127	1128	1
O	1129	1141	postbaseline
O	1142	1153	measurement
O	1154	1156	of
O	1157	1161	uNTx
O	1162	1164	at
O	1165	1169	week
O	1170	1172	25
O	1172	1173	,
B-iv-bin-percent	1174	1176	52
I-iv-bin-percent	1176	1177	%
O	1178	1179	(
B-iv-bin-abs	1179	1182	109
O	1183	1185	of
B-intervention-participants	1186	1189	208
O	1189	1190	)
O	1191	1193	of
O	1194	1203	denosumab
O	1203	1204	-
O	1204	1211	treated
O	1212	1220	patients
O	1221	1224	and
B-cv-bin-percent	1225	1227	46
I-cv-bin-percent	1227	1228	%
O	1229	1230	(
B-cv-bin-abs	1230	1232	19
O	1233	1235	of
B-control-participants	1236	1238	41
O	1238	1239	)
O	1240	1242	of
O	1243	1245	IV
O	1246	1248	BP
O	1248	1249	-
O	1249	1256	treated
O	1257	1265	patients
B-outcome	1266	1274	achieved
I-outcome	1275	1276	>
I-outcome	1276	1278	65
I-outcome	1278	1279	%
I-outcome	1280	1284	uNTx
I-outcome	1284	1285	/
I-outcome	1285	1287	Cr
I-outcome	1288	1297	reduction
O	1297	1298	.

O	1299	1301	On
O	1301	1302	-
O	1302	1307	study
B-outcome	1308	1312	SREs
O	1313	1321	occurred
O	1322	1324	in
B-iv-bin-percent	1325	1327	12
I-iv-bin-percent	1327	1328	%
O	1329	1330	(
B-iv-bin-abs	1330	1332	26
O	1333	1335	of
B-intervention-participants	1336	1339	211
O	1339	1340	)
O	1341	1343	of
O	1344	1353	denosumab
O	1353	1354	-
O	1354	1361	treated
O	1362	1370	patients
O	1371	1374	and
B-cv-bin-percent	1375	1377	16
I-cv-bin-percent	1377	1378	%
O	1379	1380	(
B-cv-bin-abs	1380	1381	7
O	1382	1384	of
B-control-participants	1385	1387	43
O	1387	1388	)
O	1389	1391	of
O	1392	1394	IV
O	1395	1397	BP
O	1397	1398	-
O	1398	1405	treated
O	1406	1414	patients
O	1414	1415	.

B-outcome	1416	1423	Overall
I-outcome	1424	1429	rates
I-outcome	1430	1432	of
I-outcome	1433	1440	adverse
I-outcome	1441	1447	events
O	1448	1452	were
B-iv-bin-percent	1453	1455	95
I-iv-bin-percent	1455	1456	%
O	1457	1459	in
O	1460	1469	denosumab
O	1470	1473	and
O	1474	1476	IV
O	1477	1479	BP
O	1480	1486	groups
O	1486	1487	.

O	1488	1490	No
O	1491	1500	denosumab
O	1500	1501	-
O	1501	1508	related
O	1509	1516	serious
O	1517	1519	or
O	1520	1525	fatal
B-outcome	1526	1533	adverse
I-outcome	1534	1540	events
O	1541	1549	occurred
O	1549	1550	.

O	1551	1553	In
O	1554	1556	IV
O	1557	1559	BP
O	1559	1560	-
O	1560	1562	na
O	1562	1563	ï
O	1563	1565	ve
O	1566	1572	breast
O	1573	1579	cancer
O	1580	1588	patients
O	1589	1593	with
O	1594	1598	bone
O	1599	1609	metastases
O	1609	1610	,
O	1611	1620	denosumab
O	1621	1631	suppresses
O	1632	1636	bone
O	1637	1645	turnover
O	1646	1649	and
O	1650	1655	seems
O	1656	1658	to
O	1659	1665	reduce
O	1666	1669	SRE
O	1670	1674	risk
O	1675	1684	similarly
O	1685	1687	to
O	1688	1690	IV
O	1691	1694	BPs
O	1694	1695	,
O	1696	1700	with
O	1701	1702	a
O	1703	1709	safety
O	1710	1717	profile
O	1718	1728	consistent
O	1729	1733	with
O	1734	1736	an
O	1737	1745	advanced
O	1746	1752	cancer
O	1753	1763	population
O	1764	1773	receiving
O	1774	1782	systemic
O	1783	1790	therapy
O	1790	1791	.
